Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, University Health Network, Toronto, Ontario, Canada.
BMJ Open. 2024 Jan 19;14(1):e074191. doi: 10.1136/bmjopen-2023-074191.
The intersection of race and older age compounds existing health disparities experienced by historically marginalised communities. Therefore, racialised older adults with cancer are more disadvantaged in their access to cancer clinical trials compared with age-matched counterparts. To determine what has already been published in this area, the rapid scoping review question are: what are the barriers, facilitators and potential solutions for enhancing access to cancer clinical trials among racialised older adults?
We will use a rapid scoping review methodology in which we follow the six-step framework of Arksey and O'Malley, including a systematic search of the literature with abstract and full-text screening to be conducted by two independent reviewers, data abstraction by one reviewer and verification by a second reviewer using an Excel data abstraction sheet. Articles focusing on persons aged 18 and over who identify as a racialised person with cancer, that describe therapies/therapeutic interventions/prevention/outcomes related to barriers, facilitators and solutions to enhancing access to and equity in cancer clinical trials will be eligible for inclusion in this rapid scoping review.
All data will be extracted from published literature. Hence, ethical approval and patient informed consent are not required. The findings of the scoping review will be submitted for publication in a peer-reviewed journal and presentation at international conferences.
种族和年龄的交集加剧了历史上边缘化社区所经历的现有健康差距。因此，与年龄匹配的同龄人相比，患有癌症的老年少数族裔在参与癌症临床试验方面处于更加不利的地位。为了确定在这一领域已经发表了哪些内容，本次快速范围审查的问题是：有哪些障碍、促进因素和潜在解决方案可以增强少数族裔老年癌症患者参与癌症临床试验的机会？
我们将采用快速范围审查方法，遵循 Arksey 和 O'Malley 的六步框架，包括对文献进行系统搜索，并由两名独立审查员进行摘要和全文筛选、由一名审查员进行数据提取以及使用 Excel 数据提取表由第二名审查员进行验证。本次快速范围审查将纳入符合以下条件的文章：年龄在 18 岁及以上、自认为是癌症少数族裔患者的人群、描述与增强和公平参与癌症临床试验的障碍、促进因素和解决方案相关的疗法/治疗干预/预防/结果的文章。
所有数据都将从已发表的文献中提取。因此，不需要伦理批准和患者知情同意。范围审查的结果将提交给同行评议期刊发表，并在国际会议上展示。
